Condition (MeSH)
Pulmonary Veno-Occlusive Disease
ClinicalTrials.gov lists 2 trials for Pulmonary Veno-Occlusive Disease or a narrower condition beneath it. Hospital Authority, Hong Kong has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
2 of the 2 trials are tagged with Pulmonary Veno-Occlusive Disease itself; the rest are tagged with a narrower condition beneath it.
When did Pulmonary Veno-Occlusive Disease trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2008 | 1 |
| 2004 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pulmonary Veno-Occlusive Disease trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Not applicable | 1 |
How many Pulmonary Veno-Occlusive Disease trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pulmonary Veno-Occlusive Disease trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Hospital Authority, Hong Kong | 1 |
Which serious adverse events do Pulmonary Veno-Occlusive Disease trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Infection | 5 | 1 |
| Gastrointestinal Toxicity | 4 | 1 |
| Bone Marrow Suppression | 2 | 1 |
| Hospitalization | 2 | 1 |
| Tremors | 1 | 1 |
Which publications cover Pulmonary Veno-Occlusive Disease? (25)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Screening for pulmonary veno-occlusive disease in heterozygous <i>EIF2AK4</i> variant carriers. | The European respiratory journal | 2022 | Yes |
| 3D heart model guides complex stent angioplasty of pulmonary venous baffle obstruction in a Mustard repair of D-TGA. | International journal of cardiology | 2014 | Yes |
| Lung transplant is a viable treatment option for patients with congenital and acquired pulmonary vein stenosis. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation | 2013 | Yes |
| Possible role of imatinib in clinical pulmonary veno-occlusive disease. | The European respiratory journal | 2008 | Yes |
| Management of congenital and acquired pulmonary vein stenosis. | The Annals of thoracic surgery | 2006 | Yes |
Showing 5 of 25 publications.
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Pulmonary venoocclusive disease | Annual incidence | <1 / 1 000 000 | France | Not stated | Unspecified |
| Pulmonary venoocclusive disease | Annual incidence | <1 / 1 000 000 | France | Not stated | Exact |
| Pulmonary venoocclusive disease | Point prevalence | Unknown | Europe | Not stated | Exact |
| Pulmonary venoocclusive disease | Point prevalence | Unknown | Europe | Not stated | Exact |
| Pulmonary venoocclusive disease | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Pulmonary venoocclusive disease | 31837 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Pulmonary venoocclusive disease | 31837 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.